Weekly Research Analysts’ Ratings Changes for Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals (NASDAQ: JAZZ) has recently received a number of price target changes and ratings updates:

• 2/27/2026 – Jazz Pharmaceuticals is now covered by Barclays PLC. They set an “overweight” rating and a $224.00 price target on the stock.
• 2/25/2026 – Jazz Pharmaceuticals had its price target raised by Royal Bank Of Canada from $191.00 to $195.00. They now have an “outperform” rating on the stock.
• 2/25/2026 – Jazz Pharmaceuticals had its price target raised by Morgan Stanley from $225.00 to $226.00. They now have an “overweight” rating on the stock.
• 2/25/2026 – Jazz Pharmaceuticals had its price target raised by Wells Fargo & Company from $235.00 to $250.00. They now have an “overweight” rating on the stock.
• 2/25/2026 – Jazz Pharmaceuticals had its price target raised by Bank of America Corporation from $263.00 to $275.00. They now have a “buy” rating on the stock.
• 1/29/2026 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen.
• 1/12/2026 – Jazz Pharmaceuticals had its price target raised by Needham & Company LLC from $210.00 to $235.00. They now have a “buy” rating on the stock.
• 1/12/2026 – Jazz Pharmaceuticals had its price target raised by Truist Financial Corporation from $220.00 to $230.00. They now have a “buy” rating on the stock.
• 1/8/2026 – Jazz Pharmaceuticals had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $225.00 price target on the stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 5,343 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $194.49, for a total value of $1,039,160.07. Following the completion of the sale, the senior vice president directly owned 28,728 shares of the company’s stock, valued at approximately $5,587,308.72. This represents a 15.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 55,600 shares of the firm’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $191.56, for a total value of $10,650,736.00. Following the transaction, the executive vice president directly owned 56,862 shares in the company, valued at approximately $10,892,484.72. This represents a 49.44% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 68,966 shares of company stock valued at $13,181,406. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.